Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable
and clear relationships exist between exposure and treatment outcomes, fixed dosing is still …

There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM)
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …

Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …

Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …

The therapeutic activity of drugs can be optimized by establishing an individualized dosage,
based on the measurement of the drug concentration in the serum, particularly if the drugs …

Background: New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase
inhibitors, pose challenges to the current phase I paradigm of dose selection based on …

Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly
become an established factor in daily (hemato)-oncology practice. Although the oral route of …

Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of
antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional …

Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …

Selective kinase inhibitors have emerged as an important class of anticancer agents, with
demonstrated clinical efficacy and generally favorable toxicity profiles in several common …